PHI Board member Jan Richardsson recently divested 5 328 shares in the company.
“The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.
After the sale, Richardsson owns 38 634 shares in PHI, privately and via companies.
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
PHI and RegenMed Development Organization have entered a partnership to advance large-scale biomanufacturing of cell-based therapies.
The strategic shift to focus on digital sales & marketing has been successful, reflected in the sales increase during the latter part of the fiscal year.
